Actinium Pharmaceuticals (ATNM) Earnings Date, Estimates & Call Transcripts → [FREE Ticket] 27 Crypto Experts Reveal Their #1 Picks (From Crypto 101 Media) (Ad) Free ATNM Stock Alerts $9.83 +0.10 (+1.03%) (As of 05/16/2024 ET) Add Compare Share Share EarningsStock AnalysisAnalyst ForecastsChartEarningsHeadlinesOwnershipShort InterestStock AnalysisAnalyst ForecastsChartEarningsHeadlinesOwnershipShort Interest Earnings SummaryLatest Earnings DateApr. 26EstimatedActual EPS (Apr. 26) -$0.31 Beat By $0.11 Consensus EPS (Apr. 26) -$0.42 Get Actinium Pharmaceuticals Earnings AlertsEnter your email address below to receive the latest news and earnings results for ATNM and its competitors with MarketBeat's FREE daily newsletter. Skip Charts & View Estimated and Actual Earnings DataEarnings Per ShareRevenueATNM Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.ATNM Estimated and Actual Revenue by Quarter Estimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Ad Huge AlertsWhy Is Gold On a MASSIVE rally? Gold has been on a tear this year. The yellow metal has hit an all-time high of $2,4231.29 recently and the rally could be far from over. From central banks to even Costco customers, it seems everyone is buying gold these days. With Wall Street watching the gold space carefully, now is a perfect time to pay attention to this stock.This Little known Company is a uniquely structured for profit Actinium Pharmaceuticals Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateQ1 20242($0.42)$0.54$0.06Q2 20243($0.78)($0.38)($0.58)Q3 20243($0.77)($0.45)($0.58)Q4 20243($0.78)($0.37)($0.54)FY 202411($2.75)($0.66)($1.65)ATNM Earnings Date and InformationActinium Pharmaceuticals last announced its quarterly earnings data on April 26th, 2024. The biotechnology company reported ($0.31) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.42) by $0.11. Actinium Pharmaceuticals has generated ($1.71) earnings per share over the last year (($1.71) diluted earnings per share). Earnings for Actinium Pharmaceuticals are expected to grow in the coming year, from ($1.48) to $0.38 per share. Read More Actinium Pharmaceuticals Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years Time Frame * Start Date * End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueCall Transcript4/26/2024Q1 2024($0.42)($0.31)+$0.11($0.31)--3/29/2024Q4 2023($0.54)($0.33)+$0.21($0.33)-$0.08 million11/2/2023Q3 2023-($0.49)($0.49)($0.49)--8/14/2023Q2 2023($0.50)($0.58)($0.08)($0.58)--5/15/2023Q1 2023($0.42)($0.43)($0.01)($0.43)--4/3/2023Q4 2022($0.41)($0.42)($0.01)($0.42)$5.17 million- Get the Latest News and Ratings for ATNM and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Actinium Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. 11/14/2022Q3 2022($0.30)($0.38)($0.08)($0.38)$2.90 million$0.05 million11/14/2022Q3 2022($0.30)($0.38)($0.08)($0.38)$2.90 million$0.05 million8/12/2022Q2 2022($0.23)($0.33)($0.10)($0.33)$1.85 million$0.05 million8/12/2022Q2 2022($0.23)($0.33)($0.10)($0.33)$1.85 million$0.05 million5/13/2022Q1 2022($0.31)($0.23)+$0.08($0.23)-$0.94 million5/13/2022Q1 2022($0.31)($0.23)+$0.08($0.23)-$0.94 million11/12/2021Q3 2021($0.29)($0.30)($0.01)($0.30)$0.28 million$0.23 million11/12/2021Q3 2021($0.29)($0.30)($0.01)($0.30)$0.28 million$0.23 million7/30/2021Q2 2021($0.30)($0.25)+$0.05($0.25)-$0.27 million7/30/2021Q2 2021($0.30)($0.25)+$0.05($0.25)-$0.27 million Actinium Pharmaceuticals Earnings - Frequently Asked Questions When did Actinium Pharmaceuticals announce their last quarterly earnings? Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) last announced its quarterly earning data on Friday, April 26, 2024. Learn more on ATNM's earnings history. Did Actinium Pharmaceuticals beat their earnings estimates last quarter? In the previous quarter, Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) reported ($0.31) earnings per share (EPS) to beat the analysts' consensus estimate of ($0.42) by $0.11. Learn more on analysts' earnings estimate vs. ATNM's actual earnings. How much revenue does Actinium Pharmaceuticals generate each year? Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) has a recorded annual revenue of $80,000.00. How much profit does Actinium Pharmaceuticals generate each year? Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) has a recorded net income of -$48.82 million. ATNM has generated -$1.71 earnings per share over the last four quarters. What is Actinium Pharmaceuticals's EPS forecast for next year? Actinium Pharmaceuticals's earnings are expected to grow from ($1.48) per share to $0.38 per share in the next year. More Earnings Resources from MarketBeat Related Companies: Design Therapeutics Earnings Results Pyxis Oncology Earnings Results 2seventy bio Earnings Results Werewolf Therapeutics Earnings Results Nektar Therapeutics Earnings Results Aldeyra Therapeutics Earnings Results Enanta Pharmaceuticals Earnings Results CytomX Therapeutics Earnings Results Xeris Biopharma Earnings Results XBiotech Earnings Results Earnings Tools: Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country: U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Australia Earnings Reports Latest Articles: Home Depot: Earnings Mixed, Wait to Buy the DipTraders Sell but Investors Still Win After Palantir's EarningsTech Earnings Insights: Where Opportunity Meets UncertaintyApple’s Earnings Show Investors Its Strength and Its WeaknessCarvana’s Q1 Earnings: A Profitability U-TurnPayPal’s Strong Earnings Growth and Strategic Evolution GE Aerospace is Ready for Liftoff After Strong Earnings This page (NYSEAMERICAN:ATNM) was last updated on 5/16/2024 by MarketBeat.com Staff From Our PartnersGold Set to EXPLODE!Gold Safe ExchangeWhy Is Gold On a MASSIVE rally? Huge AlertsThe Overlooked Retirement Asset You Probably Don’t OwnCrypto 101 MediaCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingHow Biden has already won 2024Porter & CompanyCharles Payne Demystifies OptionsUnstoppable ProsperityBiden FINISHED On June 13th?Paradigm PressBiden Nomination CANCELED?The Freeport Society Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Actinium Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.